Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 25
- Apr 30, 2025
Neoadjuvant botensilimab plus balstilimab in MMR proficient and deficient early-stage cancers: first results of the pan-cancer NEOASIS study
Chalabi et al.
Filter by
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Results from a phase 1 study of botensilimab and balstilimab in treatment refractory hepatocellular carcinoma
Apr 25
- Apr 30, 2025
El-Khoueiry, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 25
- Apr 30, 2025
Neoadjuvant botensilimab plus balstilimab in MMR proficient and deficient early-stage cancers: first results of the pan-cancer NEOASIS study
Chalabi et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR) IO
Feb 23
- Feb 26, 2025
First-line Botensilimab and Balstilimab OPtimization in Microsatellite Stable COlorectal Cancer
without liver, bone, or brain metastasis
DeVito et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR) IO
Feb 24, 2025
Biomarker Analysis From a Phase II Study of AgenT-797 (invariant natural killer T cells) with Botensilimab (Fc-enhanced CTLA-4 inhibitor) and Balstilimab (anti-PD-1) in PD-1 Refractory Gastroesophageal Cancer
Cytryn et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR) IO
Feb 24, 2025
Biomarker analysis from phase 2 study of agenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced
CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC)
Cytryn et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Journal of Clinical Oncology
Jan 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
Preliminary Results From a Randomized, Open-Label, Phase 2 Study of Botensilimab With or Without Balstilimab in Refractory Microsatellite Stable Metastatic Colorectal Cancer With No Liver Metastases
Fakih, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
A Phase I Trial of Folinic Acid, Fluorouracil, Oxaliplatin, Bevacizumab, Botensilimab, Balstilimab (FOLFOX-3B) in Microsatellite Stable Metastatic Colorectal Cancer
Fakih, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable, locally
advanced pMMR or dMMR colon cancer: results from the UNICORN trial by GONO
Ghelardi et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
Neoadjuvant Botensilimab (BOT) Plus Balstilimab (BAL) in Resectable Mismatch Repair Proficient (pMMR) and Deficient (dMMR) Colorectal Cancer (CRC)
Hissong et al.
AGENT-797 (Allogeneic iNKT Cell Therapy), Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
TPS 515: A phase II study of agenT-797 (invariant natural killer T cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
Cytryn et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Cancer Discovery
Dec 2, 2024
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy